Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
hexaxim
sanofi pasteur sa - diphtheria toxoid, tetanus toxoid, pertussis toxoid/filamentous haemagglutinin, poliovirus types 1/2/3, hepatitis b surface antigen, haemophilus infuenzae type b polysaccharide, haemophilus infuenzae type b polysaccharide conjugated to tetanus protein - suspension for injection - 20iu/0.5ml+40iu/0.5ml+25/25mcg/0.5ml+40/8/32 du/0.5ml+10mcg/0.5ml+12mcg/0.5ml+22-36mcg/0.5ml
Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
hexaxim
sanofi pasteur sa - diphtheria toxoid, tetanus toxoid, pertussis toxoid/filamentous haemagglutinin, poliovirus types 1/2/3, hepatitis b surface antigen, haemophilus infuenzae type b polysaccharide, haemophilus infuenzae type b polysaccharide conjugated to tetanus protein - suspension for injection - 20iu/0.5ml+40iu/0.5ml+25/25mcg/0.5ml+40/8/32 du/0.5ml+10mcg/0.5ml+12mcg/0.5ml+22-36mcg/0.5ml
Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
hexaxim suspension for injection
sanofi pasteur sa - diphtheria toxoid, tetanus toxoid, pertussis toxoid/filamentous haemagglutinin, poliovirus types 1/2/3, hepatitis b surface antigen, haemophilus infuenzae type b polysaccharide, haemophilus infuenzae type b polysaccharide conjugated to tetanus protein - suspension for injection - 20iu/0.5ml+ 40iu/0.5ml+ 25/25mcg/0.5ml+ 40/8/32 du/0.5ml+ 10mcg/0.5ml+ 12mcg/0.5ml+ 22-36mcg/0.5ml
Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
hexaxim suspension for injection
sanofi pasteur sa - diphtheria toxoid, tetanus toxoid, pertussis toxoid/filamentous haemagglutinin, poliovirus types 1/2/3, hepatitis b surface antigen, haemophilus infuenzae type b polysaccharide, haemophilus infuenzae type b polysaccharide conjugated to tetanus protein - suspension for injection - 20iu/0.5ml+ 40iu/0.5ml+ 25/25mcg/0.5ml+ 40/8/32 du/0.5ml+ 10mcg/0.5ml+ 12mcg/0.5ml+ 22-36mcg/0.5ml
Ireland -
English -
HPRA (Health Products Regulatory Authority)
revaxis suspension for injection in pre-filled syringe diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
sanofi pasteur - diphtheria toxoid; tetanus toxoid; poliovirus, type 1; poliovirus, type 2; poliovirus, type 3 - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - bacterial and viral vaccines, combined; diphtheria-poliomyelitis-tetanus
Ireland -
English -
HPRA (Health Products Regulatory Authority)
infanrix in a prefilled syringe %v/v suspension for injection
glaxosmithkline (ireland) limited - diphtheria toxoid tetanus toxoid pertussis toxoid filamentous haemagglutinin (fha) pertactin - suspension for injection - %v/v
European Union -
English -
EMA (European Medicines Agency)
tritanrix hepb
glaxosmithkline biologicals s.a. - diphtheria toxoid, hepatitis b surface antigen, bordetella pertussis (inactivated), tetanus toxoid - hepatitis b; tetanus; immunization; whooping cough; diphtheria - vaccines - tritanrix hepb is indicated for active immunisation against diphtheria, tetanus, pertussis and hepatitis b (hbv) in infants from six weeks onwards (see section 4.2).
Malaysia -
English -
NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
sii diphtheria and tetanus vaccine adsorbed (pediatric)-10 doses
sm pharmaceuticals sdn. bhd. - diphtheria toxoid; tetanus toxoid -
Malaysia -
English -
NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
boostrix polio suspension for injection
glaxosmithkline pharmaceutical sdn. bhd. - diphtheria toxoid; tetanus toxoid; pertussis toxoid (pt); inactivated polio virus type 3; inactivated polio virus type 2; inactivated polio virus type 1; filamentous haemagglutinin (fha); pertactin (prn) -
United States -
English -
NLM (National Library of Medicine)
daptacel (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated), clostridium tetani toxoid antigen (formaldehyde
sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) 15 [lf] in 0.5 ml - daptacel® is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to seventh birthday). a severe allergic reaction (e.g., anaphylaxis) after a previous dose of daptacel or any other tetanus toxoid, diphtheria toxoid, or pertussis-containing vaccine, or any other component of this vaccine is a contraindication to administration of daptacel. [see description (11). ] because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered. encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, inclu